398 results on '"Zabelina T"'
Search Results
2. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis
3. Bone Marrow Transplantation from Mismatched Unrelated Donors
4. Stem Cell Transplantation in Acute Myeloid Leukemia after Conditioning with Busulfan, Cyclophosphamide and Different Dosages of Etoposide (VP-16)
5. Total Marrow Irradiation (TMI), Busulfan, and Cyclophosphamide for Allografting in Multiple Myeloma. A Pilot Study
6. Comparison of the Efficacy of TAD-TAD and '7+3' Regimens in Adult AML, the Role of Dose Intensity and Mdr-1 Gene Expression
7. Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis
8. Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation
9. Donor choice according to age for allo-SCT for AML in complete remission
10. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings
11. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients
12. Evaluation of BM cytomorphology after allo-SCT in patients with AML
13. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
14. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
15. Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors
16. EXTRACORPOREAL PHOTOPHERESIS IN TREATMENT OF PATIENTS WITH STEROID REFRACTORY OR RELAPSED CHRONIC GVHD: A SINGLE CENTER RETROSPECTIVE ANALYSIS OF A ONCE WEEKLY INITIAL SCHEDULE: PH-P404
17. RAPID RESOLUTION OF BONE MARROW FIBROSIS ON DAY +100 PREDICTS OUTCOME AFTER ALLOGENEIC SCT IN MYELOFIBROSIS: PH-P100
18. REDUCING SPLEEN SIZE BY JAK INHIBITION PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS: PH-P097
19. SEVEN YEARS FOLLOW-UP OF THE PROSPECTIVE MULTICENTER STUDY OF REDUCED-INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR PRIMARY OR POST ET/PV MYELOFIBROSIS: PH-O062
20. IMPACT OF HLA-MISMATCH ON OUTCOME AFTER ATG-CONTAINING MYELOABLATIVE AND REDUCED-INTENSITY UNRELATED DONOR TRANSPLANTATION: PH-O050
21. QUALITY OF LIFE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS: PH-O058
22. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT
23. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
24. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)
25. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation
26. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up
27. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning
28. DEGRO 2004: 10. Jahreskongress der Deutschen Gesellschaft für Radioonkologie
29. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma
30. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation – a retrospective analysis
31. Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
32. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)
33. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation
34. Impact of physiological BM CD10 + CD19 + B-cell precursors (haematogones) in the post-transplant period in patients with AML
35. Evaluation of BM cytomorphology after allo-SCT in patients with MDS
36. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin
37. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors
38. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome
39. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients
40. CD34+-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation
41. Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT
42. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia
43. Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow
44. Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allogeneic stem cell transplantation: P1160
45. Evaluation of allogeneic haematopoietic stem cell transplantation and pre- and post-transplant therapy in high-risk patients with chronic myeloid leukaemia: P1151
46. In haematopoietic SCT recipients, pre- and posttransplant cytomorphologic remission status has strong prognostic relevance, but no predictive value during reduced-conditioning phase in AML patients: P936
47. Allogeneic stem cell transplantation for leukaemic transformation from MPN: A review from the EBMT database by the MDS subcommittee of the Chronic Leukaemia Working Party: O412
48. Validation of several prognositic models for prediction of survival after reduced-intensity transplantation for myelofibrosis: O411
49. Outcome of allo-SCT for chronic myelomonocytic leukemia
50. Allogeneic Stem Cell Transplantation after Reduced-Intensity Conditioning in Patients with Myelofibrosis: V549
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.